67
Participants
Start Date
February 27, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Association of Nivolumab + Relatlimab
"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
Nivolumab
"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
Institut Bergonié, Bordeaux
Institut de Cancérologie de l'Ouest - Site René Gauducheau, Nantes
Centre Léon Bérard, Lyon
Hôpital Cochin, Paris
Institut Gustave Roussy, Villejuif
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Institut Bergonié
OTHER